Ascletis Showcases Next-Generation Obesity Pipeline at ADA 2026
HONG KONG and NEW ORLEANS, Louisiana, June 8, 2026 Ascletis Pharma has strengthened its position in the highly competitive...
GLP-1 receptor agonist
Advertisement
Berobenatide Shows Strong Weight Loss With Monthly Dosing
NEW ORLEANS, Louisiana, June 6, 2026 New data presented at the American Diabetes Association (ADA) 2026 Scientific Sessions have...
Novo Nordisk Reports Strong Phase 2 Zenagamtide Data
PLAINSBORO, N.J. and BAGSVÆRD, Denmark, June 6, 2026 Novo Nordisk has announced positive results from a Phase 2 clinical...
Novo Nordisk Launches Wegovy Pill in UAE Market
BAGSVÆRD, Denmark, June 3, 2026 Novo Nordisk has announced the launch of Wegovy® pill (semaglutide tablets) in the United...
Ascletis Expands ASC30 Oral GLP-1 Program for Obesity Treatment
Hong Kong, January 26, 2026 — Ascletis Pharma continued progress in the clinical development of ASC30, its investigational oral...
Advertisements
Lilly’s Oral GLP-1 Orforglipron Sustains Weight Loss in Phase 3 Trial
Indianapolis, December 18, 2025 — Eli Lilly and Company announced positive topline results from its first-of-its-kind Phase 3 ATTAIN-MAINTAIN...
Lilly Invests $6.5 B to Build API Plant in Houston
Houston, Texas – September 23, 2025 — Eli Lilly and Company (NYSE: LLY) will invest $6.5 billion to build...
Novo Nordisk: Ozempic® Cuts Mortality and CV Events in Real-World Study
Bagsværd, Denmark – September 18, 2025 – Novo Nordisk A/S announced landmark results from the REACH real-world study showing...
Lilly’s Oral GLP-1 Outperforms Oral Semaglutide in Phase 3 Trial
INDIANAPOLIS, Sept. 17, 2025 – Eli Lilly and Company (NYSE: LLY) announced today that its investigational oral GLP-1 receptor...
Advertisement
